Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure-Reference-Cited by-同舟云学术

Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure

Published:2018-01-17 Issue:4 Volume:5 Page:562-569
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Martens Pieter¹²,Vercammen Jan¹,Ceyssens Wendy¹,Jacobs Linda¹,Luwel Evert¹,Van Aerde Herwig³,Potargent Peter³,Renaers Monique⁴,Dupont Matthias¹,Mullens Wilfried¹⁵

Affiliation:

1. Department of Cardiology; Ziekenhuis Oost-Limburg; Schiepse Bos 6 3600 Genk Belgium

2. Doctoral School for Medicine and Life Sciences; Hasselt University; Diepenbeek Belgium

3. Primary care physician region Genk; Genk Belgium

4. Clinic Care Pathway Home-Dobutamine; Wit-Geel Kruis; Limburg Belgium

5. Biomedical Research Institute, Faculty of Medicine and Life Sciences; Hasselt University; Diepenbeek Belgium

Funder

Research Foundation - Flanders

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ehf2.12248/fullpdf

Reference15 articles.

1. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology;Jaarsma;Eur J Heart Fail,2009

2. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines;Yancy;Circulation,2013

3. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population;Croft;Arch Intern Med,1999

4. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure;Ponikowski;Rev Esp Cardiol (Engl Ed),2016

5. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America;Yancy;Circulation,2017

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Effectiveness and Safety of Intermittent, Repeated, or Continuous Use of Levosimendan, Milrinone, or Dobutamine in Patients With Advanced Heart Failure: A Network and Single-Arm Meta-analysis;Journal of Cardiovascular Pharmacology;2024-07

2. Dobutamine in the Management of Advanced Heart Failure;Journal of Clinical Medicine;2024-06-27

3. Use of Inotropic Agents in Advanced Heart Failure: Pros and Cons;Cardiology;2024-01-18

4. Intravenous continuous home inotropic therapy in advanced heart failure: Insights from an observational retrospective study;European Journal of Internal Medicine;2023-10

5. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology;European Journal of Heart Failure;2023-03-10